Evidence map›Paper›PMID 24236167›Full record

ArticlePloS one2013

Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation.

Pascaline Clerc, Christina A Young, Evan A Bordt, Alina M Grigore, Gary Fiskum, Brian M Polster

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Magnesium and Migraine.Nutrients · 2025
    Review
  6. Magnesium (MgCurrent pharmaceutical design · 2024
    Review
  7. Magnesium and the Brain: A Focus on Neuroinflammation and Neurodegeneration.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pascaline ClercDepartment of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research (STAR), University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Christina A Young
Evan A Bordt
Alina M Grigore
Gary Fiskum
Brian M Polster
University of Maryland, Baltimore · US

Funding

SPECTRIN-DEPENDENT MEMBRANE DOMAINS IN THE DEVELOPING CNSP01HD016596 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI MCKENNA, MARY C · 1985 to 2013
$12.8M
Proteolytic Fragments and Mitochondrial Dysfunction in TBIR01NS064978 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI POLSTER, BRIAN M · 2009 to 2012
$1.0M
NICHD NIH HHS P01 HD016596NICHD NIH HHS P01HD016596NINDS NIH HHS R01 NS064978NINDS NIH HHS R01NS064978
6 · The paper itself

Abstract

Extracellular glutamate is elevated following brain ischemia or trauma and contributes to neuronal injury. We tested the hypothesis that magnesium sulfate (MgSO4, 3 mM) protects against metabolic failure caused by excitotoxic glutamate exposure. Rat cortical neuron preparations treated in medium already containing a physiological concentration of Mg(2+) (1 mM) could be segregated based on their response to glutamate (100 µM). Type I preparations responded with a decrease or small transient increase in oxygen consumption rate (OCR). Type II neurons responded with >50% stimulation in OCR, indicating a robust response to increased energy demand without immediate toxicity. Pre-treatment with MgSO4 improved the initial bioenergetic response to glutamate and ameliorated subsequent loss of spare respiratory capacity, measured following addition of the uncoupler FCCP, in Type I but not Type II neurons. Spare respiratory capacity in Type I neurons was also improved by incubation with MgSO4 or NMDA receptor antagonist MK801 in the absence of glutamate treatment. This finding indicates that the major difference between Type I and Type II preparations is the amount of endogenous glutamate receptor activity. Incubation of Type II neurons with 5 µM glutamate prior to excitotoxic (100 µM) glutamate exposure recapitulated a Type I phenotype. MgSO4 protected against an excitotoxic glutamate-induced drop in neuronal ATP both with and without prior 5 µM glutamate exposure. Results indicate that MgSO4 protects against chronic moderate glutamate receptor stimulation and preserves cellular ATP following treatment with excitotoxic glutamate.

Indexed as

Adenosine TriphosphateAnimalsCell RespirationCells, CulturedExcitatory Amino Acid AntagonistsGlutamic AcidGlycolysisMagnesium SulfateMitochondriaNeuronsOxygen ConsumptionPhenotypePyruvic AcidRatsReceptors, GlutamateAdenosine TriphosphateExcitatory Amino Acid AntagonistsGlutamic AcidMagnesium SulfatePyruvic AcidReceptors, Glutamate

Identifiers

PMID24236167
PMCPMC3827425
OpenAlexW2121717056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.